

Freedom of Information Act 2000 - Request Reference FoI/23/511
Intra-Vitreous Treatments

1. For the 4 months from May to August 2023, how many patients received the following intra-vitreous treatments for any eye condition:

Intra-vitreous treatments	May	June	July	August
Aflibercept - Eylea	129	111	471	565
Bevacizumab	0	0	0	0
Brolucizumab	0	0	0	0
Dexamethasone - Ozurdex	5	9	8	11
Faricimab	0	0	0	0
Ranibizumab - Lucentis	3	1	13	19
Ranibizumab - Ongavia	0	2	157	167

2. For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

Intra-vitreous treatments	May	June	July	August
Aflibercept - Eylea	0	0	14	5
Bevacizumab	0	0	0	0
Brolucizumab	0	0	0	0
Dexamethasone - Ozurdex	0	0	0	0
Faricimab	0	0	0	0
Ranibizumab - Lucentis	0	0	0	1
Ranibizumab - Ongavia	0	0	2	2